DelveInsight’s latest analysis highlights the transformative impact of the FDA’s Breakthrough Therapy Designation (BTD) for iza-bren by SystImmune and Bristol Myers Squibb. This landmark designation, announced on August 18, 2025, marks the first Breakthrough Therapy Designation in the U.S. for both companies’ collaborative drug development efforts, offering new hope for...